Valuation
- Market cap
- 3,001,008,000
- Revenue TTM
- $0
- Net income TTM
- $-446,210,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.30
Trading
- Volume
- 2,052,500
- Avg volume
- 2,977,174
- Day's range
- $15.67 – $16.33
- Shares out
- 186,746,000
- Stochastic %K
- 62%
- Beta
- 1.12
- Analysts
- Strong Sell
- Price target
- $36.00
Company profile
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and...
Show more
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 781 786 8230
- Website
- https://www.dyne-tx.com
- Address
- 1560 Trapelo Road, Waltham, United States
Latest news
No headlines yet.
